PACB - Pacific Biosciences of California - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

PACB is currently covered by 13 analysts with an average price target of $2.61. This is a potential upside of $1.52 (139.45%) from yesterday's end of day stock price of $1.09.

Pacific Biosciences of California's activity chart (see below) currently has 59 price targets and 87 ratings on display. The stock rating distribution of PACB is 36.36% HOLD and 63.64% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 58.55% with an average time for these price targets to be met of 193.53 days.

Highest price target for PACB is $4, Lowest price target is $1.5, average price target is $2.45.

Most recent stock forecast was given by KYLE MIKSON from CANACCORD on 10-Apr-2025. First documented stock forecast 27-Aug-2015.

Currently out of the existing stock ratings of PACB, 16 are a HOLD (36.36%), 28 are a BUY (63.64%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$3

$1.91 (175.23%)

$3

17 days ago
(10-Apr-2025)

5/13 (38.46%)

$1.62 (117.39%)

123

Buy

$2

$0.91 (83.49%)

$6

1 months 2 days ago
(25-Mar-2025)

2/5 (40%)

$0.69 (52.67%)

26

Hold

$2

$0.91 (83.49%)

$2.5

2 months 7 days ago
(20-Feb-2025)

6/8 (75%)

$0.23 (12.99%)

154

Hold

$1.5

$0.41 (37.61%)

$1.75

2 months 9 days ago
(18-Feb-2025)

3/6 (50%)

$-0.35 (-18.92%)

77

Buy

$2.5

$1.41 (129.36%)

$11

2 months 9 days ago
(18-Feb-2025)

0/2 (0%)

$0.65 (35.14%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is PACB (Pacific Biosciences of California) average time for price targets to be met?

On average it took 193.53 days on average for the stock forecasts to be realized with a an average price target met ratio 58.55

Which analyst has the current highest performing score on PACB (Pacific Biosciences of California) with a proven track record?

STEVEN MAH

Which analyst has the most public recommendations on PACB (Pacific Biosciences of California)?

Steven Mah works at TD COWEN and has 7 price targets and 6 ratings on PACB

Which analyst is the currently most bullish on PACB (Pacific Biosciences of California)?

Steven Mah with highest potential upside - $50.91

Which analyst is the currently most reserved on PACB (Pacific Biosciences of California)?

Doug Schenkel with lowest potential downside - -$0

Pacific Biosciences of California in the News

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most countries, sparking renewed optimism amid ongoing trade talks. The major stock indices rose as investors, growing impatient of seemingly irrational tariff...

PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results Preliminary Q1 2025Q1 2024Revenue$36.9 million$38.8 millionInstrument revenue$10.8...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?